Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
Under a Creative Commons license
open access
Keywords
Small cell lung cancer transformation
Lorlatinib
ALK G1202R solvent front mutation
Circulating tumor DNA
Rb1 C706Y
ALK+ NSCLC
Cited by (0)
© 2017 The Author(s). Published by Elsevier Ireland Ltd.